METHODS: We conducted a single-centre prospective study in children admitted to the paediatric intensive care unit for a minimum of 72 h and who developed constipation. Children with previous gastrointestinal disorders or diseases were excluded. The patients were treated with rectal enemas or with the oral PEG 3350 + E protocol at the discretion of the treating physician. We compared clinical and demographic variables as well as adverse events (diarrhoea, abdominal distension and electrolyte imbalances).
RESULTS: The sample included 56 patients with a mean age of 48.2 ± 11.9 months, of who 55.4% were male. Forty-four patients (78.6%) were treated with PEG 3350 + E and 12 (21.4%) with rectal enemas. The proportion of patients that responded well to treatment was greater in the PEG 3350 + E group (79.5%) compared to the enema group (58.3%), but the difference was not statistically significant (P = .151). There were no significant differences between the groups in any of the adverse effects. Treatment with PEG 3350 + E was more effective in children aged less than 2 years (100%) compared to older children (100% vs 65.4%; P < .01), with no significant differences in the development of adverse events.
CONCLUSIONS: The PEG 3350 + E treatment protocol for constipation in critically ill children was effective and associated with few adverse events, even in children aged less than 2 years.
方法:我们对入住儿科重症监护病房至少72小时并出现便秘的儿童进行了单中心前瞻性研究。排除先前患有胃肠道疾病或疾病的儿童。根据治疗医师的判断,对患者进行直肠灌肠或口服PEG3350+E方案治疗。我们比较了临床和人口统计学变量以及不良事件(腹泻,腹胀和电解质失衡)。
结果:样本包括56名患者,平均年龄为48.2±11.9个月,其中55.4%是男性。44例患者(78.6%)接受PEG3350E治疗,12例(21.4%)接受直肠灌肠治疗。与灌肠组(58.3%)相比,PEG3350+E组患者对治疗反应良好的比例(79.5%)更高,但差异无统计学意义(P=.151)。两组之间的任何不良反应均无显着差异。与年龄较大的儿童相比,PEG3350+E治疗2岁以下儿童(100%)更有效(100%vs65.4%;P<0.01),不良事件的发展没有显着差异。
结论:PEG3350+E治疗危重患儿便秘有效,不良反应少,即使是2岁以下的儿童。